Last updated: 21 June 2024 at 4:21pm EST

Michael Kauffman Net Worth




The estimated Net Worth of Michael Kauffman is at least $16 Million dollars as of 28 February 2022. Michael Kauffman owns over 12,452 units of Karyopharm Therapeutics Inc stock worth over $664,617 and over the last 12 years he sold KPTI stock worth over $12,111,087. In addition, he makes $3,231,500 as Co-Founder and Chief Executive Officer and Director at Karyopharm Therapeutics Inc.

Michael Kauffman KPTI stock SEC Form 4 insiders trading

Michael has made over 60 trades of the Karyopharm Therapeutics Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he sold 12,452 units of KPTI stock worth $127,508 on 28 February 2022.

The largest trade he's ever made was selling 200,000 units of Karyopharm Therapeutics Inc stock on 2 July 2014 worth over $8,500,000. On average, Michael trades about 10,792 units every 30 days since 2012. As of 28 February 2022 he still owns at least 898,131 units of Karyopharm Therapeutics Inc stock.

You can see the complete history of Michael Kauffman stock trades at the bottom of the page.





Michael Kauffman biography

Dr. Michael G. Kauffman M.D., Ph.D. serves as Co-Founder, Chief Executive Officer and Director of the Company. He serves as Co-Founder, Chief Executive Officer and Director of the Company. serves as Co-Founder, Chief Executive Officer and Director of the Company. serves as Co-Founder, Chief Executive Officer and Director of the Company. Dr. Kauffman co-founded Karyopharm with Dr. Sharon Shacham in 2008 and served as our President from January 2011 to December 2013 and as Chief Medical Officer from December 2012 to December 2013. Prior to joining Karyopharm, he was Chief Medical Officer of Onyx Pharmaceuticals Inc., a biopharmaceutical company, from November 2009 to December 2010. From November 2008 to November 2009, Dr. Kauffman was Chief Medical Officer of Proteolix Inc., which was acquired by Onyx Pharmaceuticals. At Proteolix, he led the development of Kyprolis® (carfilzomib), a novel proteasome inhibitor approved in refractory myeloma by the Food and Drug Administration in July 2012. Dr. Kauffman was an operating partner at Bessemer Venture Partners from 2006 to 2008, where he led investments in biotechnology companies. From 2006 to 2008, he was President and Chief Executive Officer of Epix Pharmaceuticals, Inc., a biopharmaceutical company that underwent liquidation proceedings through an assignment for the benefit of creditors under Massachusetts law in 2009. Dr. Kauffman was President and Chief Executive Officer of Predix Pharmaceuticals, Inc., a private biopharmaceutical company focused on G protein-coupled receptors (GPCR), from 2002 until its merger into Epix Pharmaceuticals in 2006. In that role, he led the merger of Predix Pharmaceuticals and Epix Pharmaceuticals, oversaw the discovery and development of four new clinical candidates and led collaboration transactions with Amgen and GlaxoSmithKline. From March 2000 to September 2002, Dr. Kauffman was Vice President, Clinical at Millennium Pharmaceuticals, Inc., a biopharmaceutical company, where he led the Velcade® development program.

What is the salary of Michael Kauffman?

As the Co-Founder and Chief Executive Officer and Director of Karyopharm Therapeutics Inc, the total compensation of Michael Kauffman at Karyopharm Therapeutics Inc is $3,231,500. There are 1 executives at Karyopharm Therapeutics Inc getting paid more, with Ran Frenkel having the highest compensation of $6,481,860.



How old is Michael Kauffman?

Michael Kauffman is 56, he's been the Co-Founder and Chief Executive Officer and Director of Karyopharm Therapeutics Inc since . There are 8 older and 14 younger executives at Karyopharm Therapeutics Inc. The oldest executive at Karyopharm Therapeutics Inc is Garen Bohlin, 72, who is the Independent Director.

What's Michael Kauffman's mailing address?

Michael's mailing address filed with the SEC is C/O KEZAR LIFE SCIENCES, INC., 4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA, 94080.

Insiders trading at Karyopharm Therapeutics Inc

Over the last 11 years, insiders at Karyopharm Therapeutics Inc have traded over $149,223,596 worth of Karyopharm Therapeutics Inc stock and bought 562,763 units worth $10,312,371 . The most active insiders traders include Deepika Pakianathan, Ltd Czernik Marcin Hadjimic..., and Mikael Dolsten. On average, Karyopharm Therapeutics Inc executives and independent directors trade stock every 12 days with the average trade being worth of $26,350. The most recent stock trade was executed by Michael Mano on 4 September 2024, trading 3,971 units of KPTI stock currently worth $2,859.



What does Karyopharm Therapeutics Inc do?

karyopharm therapeutics inc. is a clinical-stage pharmaceutical company focused on discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. for more information, please visit www.karyopharm.com



Complete history of Michael Kauffman stock trades at Infinity Pharmaceuticals, Karyopharm Therapeutics Inc, Verastem Inc, and Kezar Life Sciences Inc

Insider
Trans.
Transaction
Total value
Michael Kauffman
Director
Sale $127,508
28 Feb 2022
Michael Kauffman
Director
Sale $220,184
17 Feb 2022
Michael Kauffman
Director
Sale $132,824
7 Feb 2022
Michael Kauffman
Director
Sale $49,560
18 Mar 2021
Michael Kauffman
Director
Sale $281,622
18 Feb 2021
Michael Kauffman
Director
Option $669,260
11 Feb 2021
Michael Kauffman
Director
Option $462,605
5 Feb 2021
Michael Kauffman
Director
Option $225
12 Oct 2020
Michael Kauffman
Director
Option $44
17 Aug 2020
Michael Kauffman
Director
Option $225
15 Jul 2020
Michael Kauffman
Director
Option $71,250
9 Jul 2020
Michael Kauffman
Director
Option $225
22 Jun 2020
Michael Kauffman
Director
Option $225
15 Jun 2020
Michael Kauffman
Director
Option $71,250
9 Jun 2020
Michael Kauffman
Director
Option $450
15 May 2020
Michael Kauffman
Director
Option $71,250
7 May 2020
Michael Kauffman
Director
Option $95,000
8 Apr 2020
Michael Kauffman
Director
Option $95,000
9 Mar 2020
Michael Kauffman
Director
Sale $290,608
19 Feb 2020
Michael Kauffman
Director
Option $670,568
15 Feb 2020
Michael Kauffman
Director
Option $95,000
10 Feb 2020
Michael Kauffman
Director
Option $95,000
9 Jan 2020
Michael Kauffman
Director
Option $95,000
9 Dec 2019
Michael Kauffman
Director
Option $95,000
8 Nov 2019
Michael Kauffman
Director
Option $95,000
1 Nov 2019
Michael Kauffman
Director
Option $95,000
16 Sep 2019
Michael Kauffman
Director
Option $375
7 Jan 2019
Michael Kauffman
Director
Option $375
7 Dec 2018
Michael Kauffman
Director
Option $45,600
26 Nov 2018
Michael Kauffman
Director
Option $1,900
19 Nov 2018
Michael Kauffman
Director
Option $375
7 Nov 2018
Michael Kauffman
Director
Option $47,500
18 Oct 2018
Michael Kauffman
Director
Option $375
8 Oct 2018
Michael Kauffman
Director
Option $47,500
18 Sep 2018
Michael Kauffman
Director
Option $375
7 Sep 2018
Michael Kauffman
Director
Option $47,500
20 Aug 2018
Michael Kauffman
Director
Option $375
7 Aug 2018
Michael Kauffman
Director
Option $21,700
18 Jul 2018
Michael Kauffman
Director
Option $375
9 Jul 2018
Michael Kauffman
Director
Option $2,600
18 Jun 2018
Michael Kauffman
Director
Option $2,600
7 Jun 2018
Michael Kauffman
Director
Option $2,600
18 May 2018
Michael Kauffman
Director
Option $2,600
7 May 2018
Michael Kauffman
Director
Option $2,600
18 Apr 2018
Michael Kauffman
Director
Option $2,600
9 Apr 2018
Michael Kauffman
Director
Option $2,600
19 Mar 2018
Michael Kauffman
Director
Option $2,600
7 Mar 2018
Michael Kauffman
Director
Option $2,600
20 Feb 2018
Michael Kauffman
Director
Option $2,600
7 Feb 2018
Michael Kauffman
Director
Option $2,600
18 Jan 2018
Michael Kauffman
Director
Option $2,600
8 Jan 2018
Michael Kauffman
Director
Option $2,600
18 Dec 2017
Michael Kauffman
Director
Option $2,600
7 Dec 2017
Michael Kauffman
Director
Sale $1,650,000
12 Jan 2015
Michael Kauffman
Director
Sale $8,500,000
2 Jul 2014
Michael Kauffman
Director
Sale $835,200
17 Jun 2014
Michael Kauffman
Option $29,550
3 Jan 2022
Michael Kauffman
Director
Buy $29,960
28 Sep 2018
Michael Kauffman
Director
Sale $23,580
19 Mar 2015
Michael Kauffman
Director
Buy $27,300
17 Sep 2014


Karyopharm Therapeutics Inc executives and stock owners

Karyopharm Therapeutics Inc executives and other stock owners filed with the SEC include: